peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

The 2014 Annual General Meeting of Hansa Medical has been rescheduled to June 3

3 Apr 2014, 14:00
Regulatory information
Hansa Medical announces that the Annual General Meeting (AGM) has been rescheduled from May 7 to June 3. The AGM will be held at 18:00 at Scheelevägen 22 in Lund. A separate notice of the AGM will be published at the latest four weeks prior to the scheduled AGM.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser. The information in this press release is such information that Hansa Medical AB (publ) is obliged to disclose under the Securities Market Act and/or the Financial Instruments Trading Act. The information was made public on April 3, 2014 at 14:00 CET.